Cepheid's TB, Drug-Resistance Assay Shines as POC Test in Developing World
September 02, 2010
Cepheid's TB, Drug-Resistance Assay Shines as POC Test in Developing World
Cepheid's Xpert MTB/RIF test received a vote of confidence for its ability to diagnose TB and rifampicin resistance in remote and resource-poor regions of the world, according to the results of a New England Journal of Medicine study.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Dx Focus: PEPFAR Funding Drives Cepheid TB Test Uptake; Curetis Starts US Trials for MDx System
December 6, 2012 / PCR Insider - Unitaid Provides $30M to Reduce Cost, Increase Uptake of Cepheid TB Test in Developing World
June 14, 2012 / PCR Insider - UNC Team Wins NIH Grant to Study Treatment Outcomes of TB Patients Diagnosed with Cepheid Test
April 12, 2012 / PCR Insider - FIND Study Shows Cepheid TB Test Performs Well in Remote Labs, Reduces Time to Treatment
April 21, 2011 / PCR Insider - Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider